Coxib-inhibition of Duodenal Polyp Growth in FAP

Duodenal Polyposis Clinical Trial

Official title: Coxib-inhibition of Duodenal Polyp Growth in Familial Adenomatous Polyposis

Status Terminated

Clinical Trial Summary

Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenomatous Polyposis Coli
• Duodenal Polyposis

• NCT number: NCT00844727
• Study type: Interventional
• Source: Oslo University Hospital
• Status: Terminated
• Phase: Phase 2/Phase 3
• Start date: September 2003
• Completion date: April 2004